These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

350 related items for PubMed ID: 11100022

  • 1. Analysis of current data on the use of intravenous immunoglobulins in management of pemphigus vulgaris.
    Engineer L, Bhol KC, Ahmed AR.
    J Am Acad Dermatol; 2000 Dec; 43(6):1049-57. PubMed ID: 11100022
    [Abstract] [Full Text] [Related]

  • 2. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment.
    Ahmed AR.
    J Am Acad Dermatol; 2001 Nov; 45(5):679-90. PubMed ID: 11606916
    [Abstract] [Full Text] [Related]

  • 3. An 'n-of-1' placebo-controlled crossover trial of intravenous immunoglobulin as adjuvant therapy in refractory pemphigus vulgaris.
    Arnold DF, Burton J, Shine B, Wojnarowska F, Misbah SA.
    Br J Dermatol; 2009 May; 160(5):1098-102. PubMed ID: 19222460
    [Abstract] [Full Text] [Related]

  • 4. Steroid sparing effect of intravenous immunoglobulin therapy in patients with pemphigus foliaceus.
    Sami N, Qureshi A, Ahmed AR.
    Eur J Dermatol; 2002 May; 12(2):174-8. PubMed ID: 11872417
    [Abstract] [Full Text] [Related]

  • 5. The role of IVIg treatment in severe pemphigus vulgaris.
    Baum S, Scope A, Barzilai A, Azizi E, Trau H.
    J Eur Acad Dermatol Venereol; 2006 May; 20(5):548-52. PubMed ID: 16684282
    [Abstract] [Full Text] [Related]

  • 6. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid.
    Gürcan HM, Ahmed AR.
    Ann Pharmacother; 2007 Oct; 41(10):1604-10. PubMed ID: 17785614
    [Abstract] [Full Text] [Related]

  • 7. Cytokine profiles in pemphigus vulgaris patients treated with intravenous immunoglobulins as compared to conventional immunosuppressive therapy.
    Keskin DB, Stern JN, Fridkis-Hareli M, Razzaque Ahmed A.
    Cytokine; 2008 Mar; 41(3):315-21. PubMed ID: 18289869
    [Abstract] [Full Text] [Related]

  • 8. Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid.
    Gürcan HM, Ahmed AR.
    Br J Dermatol; 2009 Oct; 161(4):723-31. PubMed ID: 19548961
    [Abstract] [Full Text] [Related]

  • 9. [Treatment of juvenile pemphigus vulgaris with intravenous immunoglobulins].
    Szép Z, Danilla T, Buchvald D.
    Cas Lek Cesk; 2005 Oct; 144(10):700-3. PubMed ID: 16279438
    [Abstract] [Full Text] [Related]

  • 10. High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: evaluation of its use in 19 cases.
    Segura S, Iranzo P, Martínez-de Pablo I, Mascaró JM, Alsina M, Herrero J, Herrero C.
    J Am Acad Dermatol; 2007 Jun; 56(6):960-7. PubMed ID: 17368865
    [Abstract] [Full Text] [Related]

  • 11. Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris.
    Sami N, Qureshi A, Ruocco E, Ahmed AR.
    Arch Dermatol; 2002 Sep; 138(9):1158-62. PubMed ID: 12224976
    [Abstract] [Full Text] [Related]

  • 12. Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins.
    Shimanovich I, Nitschke M, Rose C, Grabbe J, Zillikens D.
    Br J Dermatol; 2008 Feb; 158(2):382-8. PubMed ID: 18070210
    [Abstract] [Full Text] [Related]

  • 13. Oropharyngeal pemphigus vulgaris and clinical remission: a long-term, longitudinal study.
    Mignogna MD, Fortuna G, Leuci S, Ruoppo E.
    Am J Clin Dermatol; 2010 Feb; 11(2):137-45. PubMed ID: 20141235
    [Abstract] [Full Text] [Related]

  • 14. Pemphigus vulgaris: the role of IL-1 and IL-1 receptor antagonist in pathogenesis and effects of intravenous immunoglobulin on their production.
    Bhol KC, Desai A, Kumari S, Colon JE, Ahmed AR.
    Clin Immunol; 2001 Aug; 100(2):172-80. PubMed ID: 11465946
    [Abstract] [Full Text] [Related]

  • 15. Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment.
    Ahmed AR.
    J Am Acad Dermatol; 2001 Dec; 45(6):825-35. PubMed ID: 11712025
    [Abstract] [Full Text] [Related]

  • 16. Use of intravenous immunoglobulin therapy during pregnancy in patients with pemphigus vulgaris.
    Ahmed AR, Gürcan HM.
    J Eur Acad Dermatol Venereol; 2011 Sep; 25(9):1073-9. PubMed ID: 21143649
    [Abstract] [Full Text] [Related]

  • 17. IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris.
    Bystryn JC, Jiao D.
    Autoimmunity; 2006 Nov; 39(7):601-7. PubMed ID: 17101504
    [Abstract] [Full Text] [Related]

  • 18. Analysis of thromboembolic risk related to high-dose intravenous immunoglobulin treatment: a preliminary clinical study of 10 patients with autoimmune mucocutaneous blistering diseases.
    Mignogna MD, Fortuna G, Leuci S, Ruoppo E, Adamo D, Fedele S.
    Clin Exp Dermatol; 2009 Mar; 34(2):145-50. PubMed ID: 19187294
    [Abstract] [Full Text] [Related]

  • 19. Treatment of pemphigus vulgaris with pulse intravenous cyclophosphamide.
    Pandya AG, Sontheimer RD.
    Arch Dermatol; 1992 Dec; 128(12):1626-30. PubMed ID: 1456758
    [Abstract] [Full Text] [Related]

  • 20. Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up.
    Sami N, Letko E, Androudi S, Daoud Y, Foster CS, Ahmed AR.
    Ophthalmology; 2004 Jul; 111(7):1380-2. PubMed ID: 15234140
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.